Kestra (KMTS) Q3 2026: Gross Margin Expands 900bps as Territory Buildout Drives 63% Growth

2026-03-17 | By EarningsIQ Research

Kestra’s Q3 showed a step-change in operating leverage, with gross margin up 900bps year-over-year and sequential prescription gains outpacing territory expansion. Commercial investments are translating into market share capture and higher in-network revenue mix, while algorithm and market access wins set the stage for further durable growth. Management’s confidence in scaling the rental model and pushing toward 70%+ gross margins is underpinned by a strong balance sheet and accelerating topline.

Summary

• Margin Expansion Momentum: Nine consecutive quarters of gross margin growth signal deepening operating leverage.
• Territory Scale Drives Share Gains: New and existing reps are fueling both market share shift and early market expansion.
• Strategic Access Wins: Florida Medicaid and VA network entry unlock incremental growth and margin tailwinds.

Performance Analysis

Kestra delivered 63% revenue growth year-over-year, driven by a 58% rise in prescriptions and continued market share wins in wearable cardioverter defibrillators (WCD), a device for cardiac event protection post-hospitalization. Gross margin reached 52.6%, up 900bps YoY and 200bps sequentially, marking the ninth straight quarter of improvement. This expansion reflects the inherent operating leverage in the company’s rental model—where recurring device rentals and a growing in-network payer mix drive higher revenue per fit and lower cost per fit as volumes scale.

Prescription growth was broad-based, with both legacy reps and new territory managers contributing. Notably, about 70–75% of prescription gains came from market share shift within the existing prescriber base, while 25% stemmed from new prescribers, indicating early but meaningful market expansion. The company’s conversion rate—a measure of prescriptions that convert to paid rentals—improved to 46%, up from 43% a year ago, aided by advances in revenue cycle management (RCM) and payer contracting. Operating expenses rose due to investments in commercial expansion and public company costs, but operating leverage is beginning to materialize as scale builds.

• Prescription Acceleration: Sequential script growth reached a company record, outpacing historical trends and reflecting both territory productivity and new account activation.
• In-Network Mix Uplift: In-network patient fittings rose to the low 80% range, up from 70% at IPO, supporting higher revenue per fit and RCM efficiency.
• Cost Per Fit Decline: Disposable cost improvements and volume leverage contributed to the gross margin step-up, with further gains expected as new inventory cycles in.

The topline acceleration and margin expansion are reinforcing Kestra’s confidence in achieving 70%+ gross margins over time, as the business transitions from market share shift to broader category growth and deeper payer penetration.

Executive Commentary

Strategic Positioning

1. Rental Model Economics

Kestra’s core business is the rental of wearable cardioverter defibrillators (WCDs), providing post-discharge cardiac protection. The model benefits from recurring revenue per patient and significant margin leverage as device utilization and in-network payer coverage increase. With 9 consecutive quarters of gross margin expansion and a clear path to 70%+, the economics are proving defensible as scale builds.

2. Commercial Expansion and Territory Buildout

The company has aggressively grown its sales force, targeting 130 territories by April 2026, up from 100 at year-end. This expansion is not only capturing share from the incumbent but also activating new prescribers. Management emphasizes that both new and existing reps are ramping productivity, and the model does not require perpetual territory additions for growth—productivity improvements and innovation are expected to drive ongoing gains.

3. Payer and Market Access Milestones

Entry into Florida’s managed Medicaid and the federal VA network unlocks substantial new patient pools, especially in high-share states where reimbursement barriers previously capped market penetration. These wins also create incremental margin tailwinds by converting previously uncompensated fittings to paid, in-network revenue.

4. Product and Clinical Differentiation

Recent FDA approval of a new Assure algorithm update further lowers false alarms and inappropriate shock rates, deepening product differentiation. Integration with BioBeat’s ambulatory blood pressure monitoring aims to expand diagnostic value and address the large hypertensive patient segment, supporting future market share gains and potential expansion of clinical guidelines.

5. Revenue Cycle and Automation Investments

Ongoing RCM and AI automation investments are improving conversion rates and collections, with all key RCM KPIs trending positively. This strengthens cash flow visibility and supports the company’s path toward profitability as scale builds.

Key Considerations

Kestra’s Q3 demonstrated that commercial expansion and payer access investments are translating into tangible financial and strategic gains, but the competitive and regulatory landscape remains dynamic as the company pushes for broader category adoption.

Key Considerations:

• Market Share Shift Dominates Near-Term Growth: Most prescription gains still come from incumbent share capture, with true market expansion in early stages.
• Clinical Data as a Strategic Lever: The ACE-PASS study and algorithm updates are central to both prescriber conversion and future clinical guideline changes.
• Sales Force Ramp and Productivity: New territory managers are performing to model, but ongoing training and retention will be critical as the footprint scales further.
• Cash Burn and CapEx Discipline: Management is investing in inventory and field support ahead of territory expansion, with CapEx expected to run ~$30M annually as the installed base grows.
• Regulatory and Reimbursement Milestones: Florida Medicaid and VA access are inflection points, but full impact will phase in over several quarters as contracts and operational rollouts complete.

Risks

Kestra’s growth trajectory is exposed to competitive pushback from entrenched incumbents, particularly as new products or service models launch. Market expansion depends on changes to clinical guidelines, which can be a slow and uncertain process. Reimbursement dynamics—especially with over 3,000 payers in the U.S.—pose ongoing complexity, and the shift toward profitability will require continued RCM and cost discipline as commercial investments peak.

Forward Outlook

For Q4 and full-year 2026, Kestra guided to:

• Full-year revenue of $93 million, up from prior guidance of $91 million and initial guidance of $85 million.

Management expects:

• Continued strong prescription growth as new territories mature and in-network mix rises.
• Further gross margin expansion as cost per fit declines and payer access improves.

Leadership reiterated confidence in delivering “top-tier MedTech growth” in FY27, with more detailed guidance to come after Q4.

Takeaways

Kestra’s Q3 results highlight a business model scaling rapidly on both the top and bottom line, with commercial investments and payer wins compounding margin expansion. The company is executing on its plan to build a durable growth engine, but the next phase will depend on broadening prescriber adoption, deepening payer penetration, and sustaining operational discipline as scale accelerates.

• Operating Leverage Realized: Gross margin expansion and revenue scaling validate the rental model’s economics and market opportunity.
• Commercial and Access Investments Paying Off: Territory buildout and payer wins are translating into higher in-network revenue and incremental margin tailwinds.
• Market Expansion Still in Early Innings: Clinical data and access wins are setting the stage for broader adoption, but doubling or tripling the market will require guideline changes and sustained commercial execution.

Conclusion

Kestra’s Q3 confirms the company’s ability to scale its rental model with improving economics, leveraging clinical data, payer access, and commercial execution to accelerate share gains and margin expansion. The foundation for durable growth is in place, but the next chapters will test the company’s ability to convert category leadership into long-term market expansion and profitability.

Industry Read-Through

Kestra’s accelerating revenue and margin expansion provide a clear read-through for the broader MedTech and digital health sector: rental and recurring models with strong payer mix and RCM discipline can achieve rapid operating leverage when paired with clinical differentiation. The evolution of the WCD market—driven by new clinical evidence and payer access—signals that entrenched device incumbents are vulnerable to data-driven challengers with superior service and technology. For industry peers, the importance of payer contracting, territory productivity, and continuous product improvement is reinforced as key levers for both growth and defensibility in high-acuity, post-acute care markets.

KMTS Health Care Medical Devices Recurring Revenue Wearable Devices Payer Access Gross Margin Commercial Expansion